EA201891240A1 - 1,3,4-тиадиазольные соединения и их применение в лечении рака - Google Patents

1,3,4-тиадиазольные соединения и их применение в лечении рака

Info

Publication number
EA201891240A1
EA201891240A1 EA201891240A EA201891240A EA201891240A1 EA 201891240 A1 EA201891240 A1 EA 201891240A1 EA 201891240 A EA201891240 A EA 201891240A EA 201891240 A EA201891240 A EA 201891240A EA 201891240 A1 EA201891240 A1 EA 201891240A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tiadiazolic
cancer
compounds
treatment
application
Prior art date
Application number
EA201891240A
Other languages
English (en)
Russian (ru)
Inventor
Морис Реймонд Верскойл Финлей
Йоханнес Вилхелмус Мария Ниссинк
Марк Дэвид Чарльз
Джеймс Мэттью Вуд
Original Assignee
Астразенека Аб
Кэнсер Рисерч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб, Кэнсер Рисерч Текнолоджи Лимитед filed Critical Астразенека Аб
Publication of EA201891240A1 publication Critical patent/EA201891240A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EA201891240A 2015-11-30 2016-11-30 1,3,4-тиадиазольные соединения и их применение в лечении рака EA201891240A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260787P 2015-11-30 2015-11-30
PCT/EP2016/079251 WO2017093300A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
EA201891240A1 true EA201891240A1 (ru) 2018-11-30

Family

ID=57421876

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891240A EA201891240A1 (ru) 2015-11-30 2016-11-30 1,3,4-тиадиазольные соединения и их применение в лечении рака

Country Status (25)

Country Link
US (1) US9938265B2 (enExample)
EP (1) EP3383871B1 (enExample)
JP (1) JP6873132B2 (enExample)
KR (1) KR20180083412A (enExample)
CN (1) CN108349967B (enExample)
AR (1) AR106876A1 (enExample)
AU (1) AU2016363719B2 (enExample)
BR (1) BR112018010812A2 (enExample)
CA (1) CA3005516C (enExample)
CL (1) CL2018001408A1 (enExample)
CO (1) CO2018006929A2 (enExample)
DK (1) DK3383871T3 (enExample)
DO (1) DOP2018000134A (enExample)
EA (1) EA201891240A1 (enExample)
ES (1) ES2759940T3 (enExample)
IL (1) IL258644A (enExample)
MX (1) MX2018006528A (enExample)
NI (1) NI201800065A (enExample)
PE (1) PE20181450A1 (enExample)
PH (1) PH12018501132A1 (enExample)
SG (1) SG11201803813UA (enExample)
SV (1) SV2018005701A (enExample)
TN (1) TN2018000126A1 (enExample)
TW (1) TW201730188A (enExample)
WO (1) WO2017093300A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10040789B2 (en) * 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN112888686B (zh) * 2018-10-16 2022-04-19 南京明德新药研发有限公司 噻二唑衍生物及其作为gls1抑制剂的应用
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777824B2 (en) * 1999-11-24 2004-11-04 Merck Sharp & Dohme Corp. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
WO2006053342A2 (en) * 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
PL2421826T3 (pl) * 2009-04-20 2014-03-31 Hoffmann La Roche Pochodne proliny jako inhibitory katepsyn
RS59705B1 (sr) 2011-11-21 2020-01-31 Calithera Biosciences Inc Heterociklični inhibitori glutaminaze
JP6275153B2 (ja) * 2012-11-16 2018-02-07 キャリセラ バイオサイエンシーズ， インコーポレイテッド ヘテロ環式グルタミナーゼ阻害剤
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
EP3092235A2 (en) * 2014-01-06 2016-11-16 Rhizen Pharmaceuticals S.A. Novel inhibitors of glutaminase
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10040789B2 (en) 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
DOP2018000134A (es) 2018-06-30
PE20181450A1 (es) 2018-09-12
CA3005516A1 (en) 2017-06-08
JP6873132B2 (ja) 2021-05-19
CO2018006929A2 (es) 2018-10-10
CA3005516C (en) 2024-04-16
PH12018501132A1 (en) 2019-01-21
NI201800065A (es) 2018-10-18
AU2016363719A8 (en) 2018-07-12
SG11201803813UA (en) 2018-06-28
US20170152254A1 (en) 2017-06-01
AR106876A1 (es) 2018-02-28
EP3383871A1 (en) 2018-10-10
DK3383871T3 (da) 2019-12-16
ES2759940T8 (es) 2020-05-20
EP3383871B1 (en) 2019-09-11
SV2018005701A (es) 2018-11-27
CN108349967A (zh) 2018-07-31
IL258644A (en) 2018-06-28
MX2018006528A (es) 2019-05-15
AU2016363719B2 (en) 2019-11-14
KR20180083412A (ko) 2018-07-20
ES2759940T3 (es) 2020-05-12
JP2019501134A (ja) 2019-01-17
BR112018010812A2 (pt) 2018-11-27
TW201730188A (zh) 2017-09-01
US9938265B2 (en) 2018-04-10
WO2017093300A1 (en) 2017-06-08
AU2016363719A1 (en) 2018-07-05
CN108349967B (zh) 2022-02-15
CL2018001408A1 (es) 2018-10-12
TN2018000126A1 (en) 2019-10-04

Similar Documents

Publication Publication Date Title
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
GEP20237506B (en) Pcsk9 antagonist compounds
MX391812B (es) Agonista fxr derivado de esteroides.
MX389672B (es) Inhibidores de ssao de aminopirimidina
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
UA111382C2 (uk) Інгібітори протеїнкінази
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
UA118149C2 (uk) Інгібітор jak
EA201791304A1 (ru) Производные изохинолина для лечения вич
MX381994B (es) Inhibidor de janus quinasa.
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
EA201990952A1 (ru) ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met
EA201891241A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
EA201891240A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
EA201692470A1 (ru) Фармацевтические комбинации
MX394245B (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
EA201891239A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2018001317A (es) Inhibidores del virus sincitial respiratorio.
EA201492104A1 (ru) Ингибитор jak1/2
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза